New trials show promise for immune checkpoint blockers in early-stage lung cancer

E

Educator

New member
A dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC).
 
You must log in or register to reply here.
Menu
Log in
Register